Literature DB >> 18695387

Do thiazides worsen metabolic syndrome and renal disease? The pivotal roles for hyperuricemia and hypokalemia.

Sirirat Reungjui1, Thongchai Pratipanawatr, Richard J Johnson, Takahiko Nakagawa.   

Abstract

PURPOSE OF REVIEW: The aims of this article are to review the current controversies related to the use of thiazide diuretics as first-line treatment of hypertension and to discuss the causal roles for hyperuricemia and hypokalemia on the adverse consequences of thiazide usage. RECENT
FINDINGS: Thiazides significantly reduce morbidity and mortality in hypertensive subjects. There remains, however, debate about thiazide usage as first-line treatment of hypertension. This negative impact of thiazides may be partially attributed to the ability of thiazides to exacerbate features of metabolic syndrome or increase the risk for developing diabetes. Several clinical trials suggest that thiazide-induced hyperuricemia and hypokalemia may account for some of these negative effects. Thiazide treatment is also associated with a decline of renal function in spite of a lowering blood pressure. In this review, we discuss the clinical and experimental evidence supporting a potential role of hyperuricemia and hypokalemia on the development of renal injury and worsening of the metabolic syndrome.
SUMMARY: Hyperuricemia and hypokalemia may have pivotal roles in the exacerbation of the metabolic syndrome in response to thiazides. We propose that controlling serum uric acid and serum potassium could improve thiazide efficacy and also reduce its risk for inducing metabolic syndrome or diabetes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18695387      PMCID: PMC2903051          DOI: 10.1097/MNH.0b013e328305b9a5

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  82 in total

Review 1.  Diuretics are preferred over angiotensin II-converting enzyme inhibitors for initial therapy of uncomplicated hypertension.

Authors:  Richard Grimm
Journal:  Am J Kidney Dis       Date:  2007-08       Impact factor: 8.860

Review 2.  Diuretics are preferred over angiotensin II-converting enzyme inhibitors for initial therapy of uncomplicated hypertension.

Authors:  Vito M Campese
Journal:  Am J Kidney Dis       Date:  2007-08       Impact factor: 8.860

3.  Thiazide-induced subtle renal injury not observed in states of equivalent hypokalemia.

Authors:  S Reungjui; H Hu; W Mu; C A Roncal; B P Croker; J M Patel; T Nakagawa; T Srinivas; K Byer; J Simoni; D Wesson; V Sitprija; R J Johnson
Journal:  Kidney Int       Date:  2007-10-10       Impact factor: 10.612

4.  Thiazide diuretics exacerbate fructose-induced metabolic syndrome.

Authors:  Sirirat Reungjui; Carlos A Roncal; Wei Mu; Titte R Srinivas; Dhavee Sirivongs; Richard J Johnson; Takahiko Nakagawa
Journal:  J Am Soc Nephrol       Date:  2007-09-12       Impact factor: 10.121

Review 5.  Systemic hypertension.

Authors:  William J Elliott
Journal:  Curr Probl Cardiol       Date:  2007-04       Impact factor: 5.200

6.  [Possibilities of using indices of vascular wall function as markers of negative metabolic effects of treatment with thiazide diuretics in patients with essential hypertension].

Authors:  A A Semenkin
Journal:  Ter Arkh       Date:  2007       Impact factor: 0.467

7.  Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors:  Jackson T Wright; Sonja Harris-Haywood; Sara Pressel; Joshua Barzilay; Charles Baimbridge; Charles J Bareis; Jan N Basile; Henry R Black; Richard Dart; Alok K Gupta; Bruce P Hamilton; Paula T Einhorn; L Julian Haywood; Syed Z A Jafri; Gail T Louis; Paul K Whelton; Cranford L Scott; Debra L Simmons; Carol Stanford; Barry R Davis
Journal:  Arch Intern Med       Date:  2008-01-28

Review 8.  Thiazide diuretic monotherapy for hypertension: diuretic's dark side just got darker.

Authors:  B H Rovin; L A Hebert
Journal:  Kidney Int       Date:  2007-12       Impact factor: 10.612

9.  Thiazide diuretics directly induce osteoblast differentiation and mineralized nodule formation by interacting with a sodium chloride co-transporter in bone.

Authors:  Melita M Dvorak; Cyrille De Joussineau; D Howard Carter; Trairak Pisitkun; Mark A Knepper; Gerardo Gamba; Paul J Kemp; Daniela Riccardi
Journal:  J Am Soc Nephrol       Date:  2007-07-26       Impact factor: 10.121

Review 10.  Effect of lipid-lowering and anti-hypertensive drugs on plasma homocysteine levels.

Authors:  Jutta Dierkes; Claus Luley; Sabine Westphal
Journal:  Vasc Health Risk Manag       Date:  2007
View more
  20 in total

Review 1.  Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics.

Authors:  Julio D Duarte; Rhonda M Cooper-DeHoff
Journal:  Expert Rev Cardiovasc Ther       Date:  2010-06

Review 2.  Elevated prevalence of abnormal glucose metabolism in patients with primary aldosteronism: a meta-analysis.

Authors:  W Chen; F Li; C He; Y Zhu; W Tan
Journal:  Ir J Med Sci       Date:  2013-08-30       Impact factor: 1.568

Review 3.  Modeling transport in the kidney: investigating function and dysfunction.

Authors:  Aurélie Edwards
Journal:  Am J Physiol Renal Physiol       Date:  2009-11-04

4.  Anthropometric variables, physical activity and dietary intakes of patients with uric acid nephrolithiasis.

Authors:  Alberto Trinchieri; Emanuele Croppi; Giovanni Simonelli; Carmine Sciorio; Emanuele Montanari
Journal:  Urolithiasis       Date:  2019-04-29       Impact factor: 3.436

Review 5.  Perspective: A Historical and Scientific Perspective of Sugar and Its Relation with Obesity and Diabetes.

Authors:  Richard J Johnson; Laura G Sánchez-Lozada; Peter Andrews; Miguel A Lanaspa
Journal:  Adv Nutr       Date:  2017-05-15       Impact factor: 8.701

6.  Increased fructose associates with elevated blood pressure.

Authors:  Diana I Jalal; Gerard Smits; Richard J Johnson; Michel Chonchol
Journal:  J Am Soc Nephrol       Date:  2010-07-01       Impact factor: 10.121

Review 7.  Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation.

Authors:  Richard J Johnson; George L Bakris; Claudio Borghi; Michel B Chonchol; David Feldman; Miguel A Lanaspa; Tony R Merriman; Orson W Moe; David B Mount; Laura Gabriella Sanchez Lozada; Eli Stahl; Daniel E Weiner; Glenn M Chertow
Journal:  Am J Kidney Dis       Date:  2018-02-27       Impact factor: 8.860

8.  Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study.

Authors:  Sonal Korgaonkar; Anca Tilea; Brenda W Gillespie; Margaret Kiser; George Eisele; Fredric Finkelstein; Peter Kotanko; Bertram Pitt; Rajiv Saran
Journal:  Clin J Am Soc Nephrol       Date:  2010-03-04       Impact factor: 8.237

Review 9.  Nonuremic indication for peritoneal dialysis for refractory heart failure in cardiorenal syndrome type II: review and perspective.

Authors:  Masaaki Nakayama
Journal:  Perit Dial Int       Date:  2013 Jan-Feb       Impact factor: 1.756

Review 10.  Which diuretic is the preferred agent for treating essential hypertension: hydrochlorothiazide or chlorthalidone?

Authors:  F Wilford Germino
Journal:  Curr Cardiol Rep       Date:  2012-12       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.